Ueda, Japan

Keiko Kuroiwa

This inventor holds 1 USPTO granted patent. Top assignee: Kotobuki Pharmaceutical Co Ltd. Active years: 2002.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Keiko Kuroiwa. Retrieved from https://idiyas.com/inventor/keiko-kuroiwa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2002

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Keiko Kuroiwa

Introduction

Keiko Kuroiwa, an esteemed inventor based in Ueda, Japan, has made significant strides in the field of pharmaceuticals. With a keen focus on advancing medication for diabetes management, she holds a patent that showcases her innovative capabilities.

Latest Patents

Kuroiwa's notable patent, titled "Ether and amide compounds preparation thereof composition containing same and use thereof as antidiabetics," signifies her dedication to improving treatment options for those affected by diabetes. This patent reflects her commitment to research and development in the pharmaceutical industry.

Career Highlights

Currently working at Kotobuki Pharmaceutical Co., Ltd., Keiko Kuroiwa has established herself as a pivotal figure in her organization. Her work not only contributes to the company's portfolio but also adds value to the healthcare sector by addressing critical medical needs.

Collaborations

Throughout her career, Kuroiwa has collaborated with esteemed colleagues such as Tsuyoshi Tomiyama and Akira Tomiyama. These partnerships have enabled her to enhance her research and expand the scope of her inventions, fostering an environment of innovation and teamwork.

Conclusion

Keiko Kuroiwa stands out as an influential inventor in the realm of pharmaceuticals. Her contribution to diabetes treatment through her patented innovations demonstrates her expertise and dedication to improving patient outcomes. As she continues her work at Kotobuki Pharmaceutical Co., Ltd., the potential for further advancements in her field remains promising.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…